secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001493152-26-010602
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement
--------------------------------------------------------------------------------

- ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.
- No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.
- Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.
- Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/0001493152-26-010602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-010602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer